Full Breakdown
BioNTech Founders Transition to New mRNA Venture
3/11/2026, 2:21:17 PM
Leadership Change at BioNTech
Ugur Sahin and Özlem Türeci, the co-founders of BioNTech, are set to leave their roles as CEO and Chief Medical Officer, respectively, by the end of 2026. They will establish a new independent biotechnology company focused on next-generation mRNA innovations. BioNTech announced that it would grant this new venture certain rights to its mRNA technology in exchange for a minority stake and potential milestone payments. The transition aims to allow both organizations to pursue distinct strategic priorities, with BioNTech concentrating on its oncology pipeline.
Background of BioNTech
Founded in 2008, BioNTech gained prominence during the COVID-19 pandemic through its partnership with Pfizer to develop the Comirnaty vaccine, which became a cornerstone in the global vaccination effort. The vaccine's success generated nearly $38 billion in sales in 2022, significantly boosting BioNTech's market value to over $20 billion. However, as vaccine sales declined with the pandemic's ebb, BioNTech has shifted its focus back to its original mission of cancer treatment, now advancing multiple late-stage clinical trials.
New Venture Focus
The new company, which remains unnamed, will leverage mRNA technology to explore innovative therapeutic avenues beyond cancer. Sahin expressed a desire to return to pioneering work, stating, “Our vision has always been to translate our science into meaningful advances for patients.” This venture marks the couple's third biotechnology initiative, following Ganymed Pharmaceuticals and BioNTech.
Financial Implications and Market Reaction
Following the announcement, BioNTech's stock experienced a significant drop, with shares falling by over 20% in early trading. Analysts have expressed concern regarding the uncertainty introduced by this leadership change, particularly as BioNTech prepares to launch multiple oncology products. Despite this, BioNTech maintains a strong financial position, with cash reserves of approximately €17.2 billion as of the end of 2025.
Official Statements & Responses
BioNTech's Supervisory Board Chairman, Helmut Jeggle, emphasized the importance of Sahin and Türeci's contributions, stating, “As BioNTech advances multiple late-stage product candidates towards commercialization, we support them in taking the opportunity to apply their strengths and undivided attention to a new venture.” The company reassured investors that its current drug development pipeline, including cancer therapies, would remain unaffected by the founders' departure.
Criticism & Opposition
Investor sentiment has been mixed, with some portfolio managers describing the founders' exit as “devastating news” for BioNTech at a critical juncture. Concerns have been raised about the potential impact on the company's trajectory as it transitions from a pandemic-focused entity to a multi-product biopharmaceutical firm.
What's Next
BioNTech expects to have around 15 Phase 3 clinical trials in oncology underway by the end of 2026, with multiple late-stage data readouts anticipated. The formal agreement regarding the new venture is expected to be finalized by mid-2026, paving the way for both companies to collaborate on future projects, particularly in combination therapies.
Verbatim Quotes
- “For us, this is the right time to prepare to hand over the baton.” — Ugur Sahin, CEO of BioNTech
- “Our vision has always been to translate our science into meaningful advances for patients, and we see extraordinary opportunities to unlock the next generation of transformative innovations.” — Ugur Sahin, CEO of BioNTech
- “This is something that takes time, and I think also there are managers that love to do that.” — Ugur Sahin, on the transition of BioNTech's focus
- “The potential of mRNA is high, and we should not be driven by anything that happens outside of the science field,” — Ugur Sahin, on the future of mRNA technology
